NCT05815784
Myopia Control: a Comparison Study Between Atropine and MiSight
Active, Not Recruiting
PHASE2Ages 5–12InterventionalTreatmentAnn & Robert H Lurie Children's Hospital of ChicagoInvestigator-initiated
~348 participants
Updated 2026-07-22 on ClinicalTrials.gov
What's tested:AtropineMiSight contact lenses
At a glance
Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
axial length
Measured over 2 years
+1 more outcome measured
Conditions
Where it's being run
1 sites across 1 statesIllinois1
Study leadership
- Magdalena Stec, OD · PRINCIPAL_INVESTIGATOR · Ann & Robert H Lurie Children's Hospital of Chicago
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Children age of 5-12 years old at their baseline exam
Children with a spherical equivalent refractive error of +0.50D (minimal hyperopia) to -7.50 D (high myopia)
Gestational age ≥ 32 weeks.
Birth weight \>1500g.
Exclusion
Current or previous form of myopia control
Current or previous use of bifocal, progressive- addition lenses, or multifocal contact lenses
Known atropine allergy or contact lens intolerance (allergy to only one can still allow enrollment in the other group)
Abnormality of cornea, lens, central retina, iris, or ciliary body
Current or prior history of manifest strabismus, amblyopia, or nystagmus
Current or previous myopia treatment with atropine, pirenzepine or another anti-muscarinic agent.
Current or previous use of bifocals, progressive-addition lenses, or multi-focal contact lenses.
Current or previous use of orthoK, rigid gas permeable, or other contact lenses being used to reduce myopia progression.
Abnormality of the cornea, lens, central retina, iris, or ciliary body.
Prior eyelid, strabismus, intraocular, or refractive surgery.
Down syndrome or cerebral palsy.
Diseases known to affect accommodation, vergence, or ocular motility (e.g., multiple sclerosis, Grave's disease, myasthenia gravis, diabetes mellitus, Parkinson's disease)
Existing ocular conditions (e.g., retinal disease, cataracts, ptosis) or systemic/neurodevelopmental conditions (e.g., Down syndrome) which may influence refractive development
Any condition that in the judgement of the investigator could potentially influence refractive development.
Existing conditions that may affect the long-term health of the eye or require regular pharmacologic treatment that may adversely interact with study medication (e.g., JIA, glaucoma, diabetes mellitus, pre-diabetes)
Inability to comprehend and/or perform any study-related clinical tests
What this trial measures
- axial length2 years
change in axial length (as measured by biometry) over a 2-year time period
- Refractive error2 years
change in refractive error over a 2-year time period